Status message

Not the entire site translated, but only to "Journal"

Neuroleptic Malignant Syndrome

E.E. Vaiman1, N.A. Shnayder  2,3, V.V. Arkhipo3, R.F. Nasyrova1
1 FGBI “V.M. Bekhterev National Medical Research Center of Psychiatry and Neurology”" of the Ministry of Health of Russia, Saint-Petersburg, Russia
2 Federal state budgetary institution of higher education “V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University”,  Krasnoyarsk, Russia.
3 Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation, Moscow Russian
Introduction:  Malignant neuroleptic syndrome is a complication that occurs while taking high doses of drugs, more often antipsychotics. Its prevalence ranges from 0.02% to 3.23%. This iatrogenic ышву уааусе develops within 4 weeks of starting therapy. Nevertheless, in 16% of patients, symptoms are recorded after 24 hours.
Objective: To analyze the results of studies reflecting the mechanisms of development, risk factors, prevalence, diagnostic criteria and principles of treatment of NMS.
Materials and methods: We searched for full-text publications in Russian and English in the E-Library, PubMed databases using keywords. The sample consisted of 111 publications, including scientific articles and monographs on this scientific issue. The search depth was 10 years. In addition, earlier publications of historical interest were included in the lecture. Despite our comprehensive search of these commonly used databases and search terms, it cannot be excluded that some publications may have been missed.
Results: The systematization of modern data on the etiology, risk factors and the theory of the pathophysiology of the NNS was carried out. It also describes the clinical picture, the criteria for making a diagnosis and possible treatment for a better understanding of practitioners who face this complication.
Contact: Nasyrova Regina, reginaf@bekhterev.ru  https://orcid.org/0000-0003-1874-9434
Citation: Vaiman E.E., Shnayder N.A., Arkhipov V.V., Nasyrova R.F. Neuroleptic Malignant Syndrome // Sovrem. ter. psih. rasstrojstv [Current Therapy of Mental Disorders]. – 2020. – No. 4. – P. 13–21. – DOI: 10.21265/PSYPH.2020.22.61.002 [in Russian] 
Conflict of interest: the authors declare no conflict of interest
 

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

References: 

1.    Delay J., Deniker P. Drug-induced extrapyramidal syndromes // Vinken P.J., Bruyn G.W. (eds.). Handbook of Clinical Neurology. – Vol. 6: Diseases of the Basal Ganglia. – Amsterdam, North-Holland, 1968. – P. 248–266.
2.    Velamoor R. Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management // Asian J Psychiatr. – 2017. – Vol. 29. – P. 106–109. – DOI: 10.1016/j.ajp.2017.05.004, PMID: 29061403
3.    Oruch R., Pryme I.F., Engelsen B.A., Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency // Neuropsychiatr Dis Treat. – 2017. – Vol. 13. – P. 161–175. – DOI: 10.2147/NDT.S118438, PMID: 28144147
4.    Delay J., Pichot P., Lemperiere T. et al. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses // Ann Med Psychol (Paris). – 1960. – Vol. 118, No. 1. – P. 145–152. – PMID: 13815606
5.    Velamoor V.R. Neuroleptic malignant syndrome. Recognition, prevention and Management // Drug Saf. – 1998. – Vol. 19 (1). – P. 73–82.
6.    Keck P.E. Jr., Sebastianelli J., Pope H.G. Jr., McElroy S.L. Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital // J Clin Psychiatry. – 1989. – Vol. 50 (9). – P. 352–355.
7.    Deng M.Z., Chen G.Q., Phillips M.R. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study // Am J Psychiatry. – 1990. – Vol. 147 (9). – P. 1149–1155. 
8.    Spivak B., Maline D.I., Kozyrev V.N. et al. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow // Eur Psychiatry. – 2000. – Vol. 15 (5). – P. 330–333. – PMID: 10954877
9.    Strawn J., Keck P.E., Caroff N. Neuroleptic malignant syndrome // Am J Psychiatry. – 2007. – Vol. 164. – P. 870–876.
10.    McAllen K.J., Schwartz D.R. Adverse drug reactions resulting in hyperthermia in the intensive care unit // Crit Care Med. – 2010. – Vol. 38. – P. S244–S252.
11.    Escobar-Vidarte M.F., Loaiza-Osorio S., Messa A.A., Macías G.E. Neuroleptic malignant syndrome in pregnancy: case report and literature review // J Matern Fetal Neonatal Med. – 2019. – Vol. 32 (14). – P. 2438–2441. – DOI: 10.1080/14767058.2018.1432591
12.    Velamoor V.R., Norman R.M., Caroff S.N. et al. Progression of symptoms in neuroleptic malignant syndrome // J NervMent Dis. – 1994. – Vol. 182 (3). – P. 168–173. 
13.    Caroff S.N., Mann S.C., Campbell E.C. Atypical antipsychotics and neuroleptic malignant syndrome // Psychiatr. Ann. – 2000. – Vol. 30 (5). – P. 314–321
14.    Pope H.G. Jr., Aizley H.G., Keck P.E. Jr., McElroy S.L. Neuroleptic malignant syndrome: long-term follow-up of 20 cases // J Clin Psychiatry. – 1991. – Vol. 52 (5). – P. 208–212. – PMID: 1674508 
15.    Drews J.D., Christopher A., Clay Evans D. Neuroleptic malignant syndrome in the trauma intensive care unit: Diagnosis and management of a rare disease in a challenging population // Int J CritIlln Inj. – 2017. – Vol. 7. – P. 119–121.
16.    García-Atienza E.M., Agudo-Mena J.L., Cuesta-Vizcaíno E. et al. Olanzapine as a cause of neuroleptic malignant syndrome, bibliographic review following a clinical case // Actas Esp Psiquiatr. – 2018. – Vol. 46 (3). – P. 112–116. – PMID: 29892970
17.    Zweig Y.R., Galvin J.E. Lewy body dementia: The impact on patients and caregivers // Alzheimers Res Ther. – 2014. – Vol. 6 (2). – P. 21. – DOI: 10.1186/alzrt251, PMID: 25031635
18.    Aarsland D., Perry R., Larsen J.P. et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias // J ClinPsychiatry. – 2005. – Vol. 66. – P. 633–637.
19.    Keck P.E. Jr., Pope H.G., Cohen B.M. et al. Risk factors for neuroleptic malignant syndrome // Arch Gen Psychiatry. – 1989. – Vol. 46. – P. 914– 918.
20.    Khaldi S., Kornreich C., Choubani Z., Gourevitch R. Antipsychotiq uesatypiques et syndrome malin des neuroleptiques: bréve revue de la littérature. [Neuroleptic malignant syndrome and atypical antipsychotics: A brief review] // Encephale. – 2008. – Vol. 34 (6). – P. 618–624.
21.    Gupta V., Magon R., Mishra B.P. et al. Risk factors in neuroleptic malignant syndrome // Indian J Psychiatry. – 2003. – Vol. 45 (1). – P. 30–35.
22.    Viejo L.F., Morales V., Punal P. et al. Risk factors in neuroleptic malignant syndrome: a case–control study // Acta Psychiatr Scand. – 2003. – Vol. 107. – P. 45–49.
23.    Berardi D., Amore M., Keck P.E. Jr. et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study // Biol Psychiatry. – 1998. – Vol. 44 (8). – P. 748–754. – DOI: 10.1016/S0006-3223(97)00530-1
24.    Sachdev P., Mason C., Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome // Am J Psychiatry. – 1997. – Vol. 154. – P. 1156–1158.
25.    Keyser D.L., Rodnitzky R.L. Neuroleptic malignant syndrome in Parkinson’s disease after withdrawal or alteration of dopaminergic therapy // Arch Intern Med. – 1991. – Vol. 151 (4). – P. 794–796.
26.    Hermesh H., Aizenberg D., Weizman A. et al. Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients // Br J Psychiatry. – 1992. – Vol. 161. – P. 254–257.
27.    Koch M., Chandragiri S., Rizvi S. et al. Catatonic signs in neuroleptic malignant syndrome // Compr Psychiatry. – 2000. – Vol. 41 (1). – P. 73–75.
28.    Alexander P.J., Thomas R.M., Das A. Is risk of neuroleptic malignant syndrome increased in the postpartum period? // J Clin Psychiatry. – 1998. – Vol. 59 (5). – P. 254–255.
29.    Su Y.P., Chang C.K., Hayes R.D. et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome // Acta Psychiatr Scand. – 2014. – Vol. 130 (1). – P. 52–60. – DOI: 10.1111/acps.12222
30.    Seitz D.P., Gill S.S. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature // Psychomatics. – 2009. – Vol. 50 (1). – P. 8–15.
31.    Gurrera R.J. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome // Am. J. Psychiatry. – 1999. – Vol. 156 (2). – P. 169–180.
32.    Kostyukova A.B., Mosolov S.N. Neirovospalitel'naya gipoteza shizofrenii i nekotorye novye terapevticheskie podkhody // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 4. – S. 2–8.
33.    Guillemin G.J., Smith D.G., Kerr S.J. et al. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis // Redox Rep. – 2000. – Vol. 5 (2–3). – P. 108–111. – PMID: 10939285
34.    Guillemin G.J., Smythe G., Takikawa O., Brew B.J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons // Glia. – 2005. – Vol. 49 (1). – P. 15–23. – PMID: 15390107
35.    Nagatsu T., Ichinose H. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin // MolNeurobiol. 1999. Vol. 19. №1. 79-96. PMID: 10321973
36.    Riddell D.R., Owen J.S. Nitric oxide and platelet aggregation // Vitam Horm. – 1999. – Vol. 57. – P. 25–48. – PMID: 10232045
37.    Jendzjowsky N.G., Just T.P., Jones K.E., De Lorey D.S. Acute tetrahydrobiopterin supplementation attenuates sympathetic vasoconstrictor responsiveness in resting and contracting skeletal muscle of healthy rats // Physiol Rep. – 2014. – Vol. 2 (10). – P. pii: e12164. – DOI: 10.14814/phy2.12164 
38.    Vásquez-Vivar J., Kalyanaraman B., Martásek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications // Free Radic Res. – 2003. – Vol. 37 (2). – P. 121–127. – PMID: 12653200
39.    Mary K., Ian J. Tetrahydrobiopterin deficiency // Natan G., Hans H.G. (eds.). Oxidative Stress and Free Radical Damage in Neurology. Oxidative Stress in Applied Basic Research and Clinical Practice. – New York, NY: Springer, 2011. – P. 225–234.
40.    Kawanishi C. Genetic predisposition to neuroleptic malignant syndrome: implications for antipsychotic therapy // Am J Pharmacogenomics. – 2003. – Vol. 3 (2). – P. 89–95.
41.    Boone M., Kortenoeven M.L.A., Robben J.H. et al. Counteracting vasopressin-mediated water reabsorption by ATP, dopamine, and phorbol esters: Mechanisms of action // American Journal of Physiology-Renal Physiology. – 2011. – Vol. 300. – P. F761–F771. – DOI: 10.1152/ajprenal.00247.2010
42.    Gildea J.J. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance // Current Opinion in Nephrology and Hypertension. – 2009. – Vol. 18. – P. 28–32. – DOI: 10.1097/ MNH.0b013e32831a9e0b
43.    Arévalo-Lorido J.C., Gómez J.C., Formiga F. et al. High serum osmolarity at admission determines a worse outcome in patients with heart failure: Is a new target emerging? // International Journal of Cardiology. – 2016. – Vol. 221. – P. 238–242. – DOI: 10.1016/j.ijcard.2016.07.084
44.    Shen Y., Cheng X., Ying M. et al. Association between serum osmolarity and mortality in patients who are critically ill: A retrospective cohort study // BMJ Open. – 2017. – Vol. 7. – P. e015729. – DOI: 10.1136/bmjopen-2016-015729
45.    Kalelioglu T., Karamustafalioglu N., Celikel G. et al. Serum osmolarity and blood viscosity as a potential explanation for the pathophysiology of neuroleptic malignant syndrome // Int J Psychiatry Clin Pract. – 2019. – Vol. 23 (4). – P. 307–310. – DOI: 10.1080/13651501.2019.1617884
46.    Tsygankov B.D. Kliniko-patogeneticheskie zakonomernosti razvitiya febril'nykh pristupov shizofrenii i sistema ikh terapii. – M.: Norma, 1997. – 232 c.
47.    Chekhonin V.P., Morozov G.V., Morkovkin V.M., Kekelidze Z.I. Immunokhimicheskoe izuchenie pronitsaemosti gematoentsefalicheskogo bar'era pri kriticheskikh sostoyaniyakh, obuslovlennykh febril'noi shizofreniei i ostrymi alkogol'nymi entsefalopatiyami // Mater. VIII s"ezda nevropat. i psikhiatr. – № 3. – M., 1988. S. 132–134.
48.    Levenson J.L. Neuroleptic malignant syndrome // Am J Psychiatry. – 1985. – Vol. 142 (10). – P. 1137–1145. – PMID: 2863986
49.    Pope H.G. Jr., Keck P.E. Jr., McElroyS.L. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital // Am J Psychiatry. – 1986. – Vol. 143 (10). – P. 1227–1233. – PMID: 2876647
50.    Addonizio G., Susman V.L., Roth S.D. Neuroleptic malignant syndrome: review and analysis of 115 cases // Biol Psychiatry. – 1987. – Vol. 22 (8). – P. 1004–1020. – PMID: 2886157
51.    Adityanjee A., Aderibigbe Y.A., Mathews T. Epidemiology of neuroleptic malignant syndrome // Clin Neuropharmacol. – 1999. – Vol. 22 (3). – P. 151–158. – PMID: 10367179
52.    Medication-induced movement disorders and other adverse effects of medication. 5th. // – Diagnostic and Statistical Manual of Mental Disorders. – Washington, DC: American Psychiatric Publishing, 2013. – P. 709–711. 
53.    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). – Arlington, VA: American Psychiatric Publishing. 2013. – 992 p. – DOI: 10.1176/appi.books.9780890425596
54.    Laboratoriya Kheliks. URL: https://helix.ru/kb/item/06-022 (data obrashcheniya 15.05.2020).
55.    Lee H.C., Kim J.M., Lim J.K. et al. Central hyperthermia treated with baclofen for patient with pontine hemorrhage // Ann Rehabil Med. – 2014. – Vol. 38 (2). – P. 269–272. – DOI: 10.5535/arm.2014.38.2.269, PMID: 24855623
56.    Sung C.Y., Lee T.H., Chu N.S. Central hyperthermia in acute stroke // Eur Neurol. – 2009. – Vol. 62 (2). – P. 86–92. – DOI: 10.1159/000222778. PMID:19521083
57.    Lancaster E. The diagnosis and treatment of autoimmune encephalitis // J Clin Neurol. – 2016. – Vol. 12 (1). – P. 1–13. – DOI: 10.3988/jcn.2016.12.1.1. PMID: 26754777
58.    Takahashi Y., Mori H., Mishina M. et al. Autoantibodies and cell-mediated utoimmunity to NMDA-type GluRepsilon2 in patients with Rasmussen's encephalitis and chronic progressive epilepsiapartialis continua // Epilepsia. – 2005. – Vol. 6 (5). – P. 152–158. – PMID: 15987271
59.    Splendiani A., Felli V., Di Sibio A. et al. Magnetic resonance imaging and magnetic resonance spectroscopy in a young male patient with anti-N-methyl-D-aspartate receptor encephalitis and uncommon cerebellar involvement: A case report with review of the literature // Neuroradiol J. – 2016. – Vol. 29 (1). – P. 30–35. – DOI: 10.1177/1971400915609333, PMID: 26613928
60.    Mosolov S.N., Kostyukova E.G., Serditov O.V. Serotoninovyi sindrom pri lechenii depressii // Mezhdunarodnyi zhurnal meditsinskoi praktiki. – 2000. – № 8. – S. 28–33.
61.    Volkov V.P. zlokachestvennaya gipertermiya. Vestnik anesteziologii i reanimatologii. –2012. – № 9 (4).– S. 47–54.
62.    Malin D.I., Malina D.D. Sindrom febril'noi katatonii pri kriticheskikh sostoyaniyakh v psikhiatrii // Sotsial'naya i klinicheskaya psikhiatriya. – 2019. – № 29 (1). – S. 82–89.
63.    Malin D.I., Ravilov R.S. Rasprostranennost', klinika, diagnostika i terapiya tyazhelykh oslozhnenii neirolepticheskoi terapii // Rossiiskii psikhiatricheskii zhurnal. – 2014. – № 24 (4). – S. 90–96.
64.    Avrutskii G.Ya. Raiskii V.A. Tsygankov B.D. Klinika i techenie zlokachestvennogo neirolepticheskogo sindroma (ostroi febril'noi neirolepticheskoi entsefalopatii) // Zhurn. nevropatol. i psikhiatr. – 1987. – № 9. – S. 1391–1397.
65.    Volkov V.P. K voprosu o febril'noi katatonii // Sotsial'naya i klinicheskaya psikhiatriya. – 2012. – № 22 (2). – C. 16–20.
66.    Konoreva A.E., Tsukarzi E.E., Mosolov S.N.. Katatoniya: patofiziologiya, diagnostika i sovremennye podkhody k lecheniyu // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2019. – № 4. – S. 2–10. – DOI: 10.21265/PSYPH.2019.17.70.001
67.    Jeong S.H., Ahn Y.M., Koo Y.J. et al. The characteristics of clozapine-induced fever // Schizophr Res. – 2002. – Vol. 56 (1–2). – P. 191–193.
68.    Young C.R., Bowers M.B. Jr., Mazure C.M. Management of the adverse effects of clozapine // Schizophr Bull. – 1998. – Vol. 24 (3). – P. 381–390.
69.    Kohen I., Afzal N., Hussain S., Manu P. Increases in C-reactive protein may predict recurrence of clozapine-induced fever // Ann Pharmacother. – 2009. – Vol. 43 (1). – P. 143–146.
70.    Bruno V., Valiente-Gomez A., Alcoverro O. Clozapine and fever: a case of continued therapy with clozapine // Clin Neuropharmacol. – 2015. – Vol. 38 (4). – P. 151–153.
71.    Dalmau J., Gleichman A.J., Hughes E.G. et al. Anti-NMDA receptor encephalitis: case series and analysis of the effects of antibodies // Lancet Neurology. – 2008. – Vol. 7 (12). – R. 1091–1098.
72.    Dalmau J., Lancaster E., Martinez-Hernandez M.R. et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis // Lancet Neurology. – 2011. – Vol. 10 (1). – R. 63–74.
73.    Malin D.I., Ryvkin P.V. Psikhofarmakologichesiki delirii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2018. – № 3. – S. 38–43. – DOI: 10.21265/PSYPH.2018.46.16770
74.    Gurovich I.Ya. Pobochnye effekty i oslozhneniya pri neirolepticheskoi terapii: dis. … d-ra med. nauk. – M., 1971. – 443 s. 
75.    Malin D.I. Pobochnye deistviya psikhotropnykh veshchestv. – M.: Vuzovskaya kniga. 2000. – 208 s.
76.    Woodbury M., Woodbury M. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome // J Am Acad Child Adolesc Psychiatry. – 1992. – Vol. 31 (6). – P. 1161–1164.
77.    Francis A., Chandragiri S., Rizvi S. et al. Is Lorazepam a treatment for neuroleptic malignant syndrome? // CNS Spectr. – 2000. – Vol. 5 (7). – P. 54–57.
78.    Khaldarov V. Benzodiazepines for treatment of neuroleptic malignant syndrome // Hosp. Phys. – 2000. – Vol. 6. – P. 51–55.
79.    Yacoub A., Francis A. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to Lorazepam // Neuropsychiatr Dis Treat. – 2006. – Vol. 2 (2). – P. 23.
80.    Krause T., Gerbershagen M.U., Fiege M., WeisshornR., Wappler F. Dantrolene – a review of its pharmacology, therapeutic use and new developments // Anaesthesia. – 2004. – Vol. 59 (4). – P. 364–373.
81.    Velamoor V.R., Swamy G.N., Parmar R.S., Williamson P., Caroff S. Management of suspected neuroleptic malignant syndrome // Can J Psychiatry. – 1995. – Vol. 40 (9). – P. 545–550.
82.    Sakkas P., Davis J.M., Janucak P.G., Wang Z.Y. Drug treatment of the neuroleptic malignant syndrome // Psychopharmacol Bull. – 1991. – Vol. 27 (3). – P. 381–384.
83.    Davis J.M., Caroff S.N., Mann S.C. Treatment of neuroleptic malignant syndrome // Psychiatr Ann. – 2000. – Vol. 30 (5). – P. 325–331.
84.    Malin D.I. Effektivnost' primeneniya plazmafereza v lechenii pobochnykh effektov i oslozhnenii neirolepticheskoi terapii // Sotsial'naya i klinicheskaya psikhiatriya. – 1993. – № 4. – S. 82–84.